| 3.41 -0.07 (-2.01%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.26 | 1-year : | 4.97 |
| Resists | First : | 3.65 | Second : | 4.26 |
| Pivot price | 3.34  |
|||
| Supports | First : | 2.99 | Second : | 2.58 |
| MAs | MA(5) : | 3.43 |
MA(20) : | 3.25 |
| MA(100) : | 2.62 |
MA(250) : | 3.42  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 68.7 |
D(3) : | 70 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 8.28 | Low : | 1.66 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MRVI ] has closed below upper band by 34.3%. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.54 - 3.56 | 3.56 - 3.58 |
| Low: | 3.33 - 3.35 | 3.35 - 3.37 |
| Close: | 3.38 - 3.41 | 3.41 - 3.44 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Wed, 22 Oct 2025
Maravai LifeSciences (NASDAQ: MRVI) sets Nov. 6, 5 p.m. ET earnings call and webcast - Stock Titan
Fri, 17 Oct 2025
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with a 14.61% Upside Potential - DirectorsTalk Interviews
Thu, 02 Oct 2025
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, - GlobeNewswire
Thu, 14 Aug 2025
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Tue, 12 Aug 2025
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 145 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 90 (%) |
| Shares Short | 13,100 (K) |
| Shares Short P.Month | 13,880 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.84 |
| Profit Margin | -87.6 % |
| Operating Margin | -75.4 % |
| Return on Assets (ttm) | -5.9 % |
| Return on Equity (ttm) | -54.9 % |
| Qtrly Rev. Growth | -31.8 % |
| Gross Profit (p.s.) | 0.46 |
| Sales Per Share | 1.51 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -2.49 |
| PEG Ratio | 0 |
| Price to Book value | 1.85 |
| Price to Sales | 2.24 |
| Price to Cash Flow | -23.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|